Date Filed | Type | Description |
07/25/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
01/04/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
01/04/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
11/07/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
07/18/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
04/12/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
01/12/2022 |
SC 13G/A
| Meditor Group Ltd reports a 7.1% stake in Esperion Therapeutics, Inc. |
01/05/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
10/14/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
07/12/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
04/09/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
01/06/2021 |
SC 13G/A
| Meditor Group Ltd reports a 9.6% stake in Esperion Therapeutics, Inc. |
01/06/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
10/19/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
07/14/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
04/30/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
01/06/2020 |
SC 13G/A
| Meditor Group Ltd reports a 9.9% stake in Esperion Therapeutics, Inc. |
01/02/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
10/31/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
07/24/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
04/09/2019 |
SC 13G/A
| Meditor Group Ltd reports a 5% stake in Exelixis, Inc. |
04/03/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
01/03/2019 |
SC 13G/A
| Meditor Group Ltd reports a 9.9% stake in Esperion Therapeutics, Inc. |
01/02/2019 |
SC 13G/A
| Meditor Group Ltd reports a 5.3% stake in Exelixis, Inc. |
01/02/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
10/09/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
07/19/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
04/20/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
01/04/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/04/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
01/03/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
10/17/2017 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
08/21/2017 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
07/21/2017 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
|